Big Chemical Encyclopedia

Chemical substances, components, reactions, process design ...

Articles Figures Tables About

Clinical utility, genetic testing

These data emphasize the complex nature of the molecular mechanisms controlling polymorphic DPD activity in vivo. The clinical utility for genetic polymorphism testing to date is not optimal because of its low sensitivity and unknown specificity (28). Overall, it can be remarked that the splice site mutation IVS14+1G>A causes severe, even lethal, 5-FU-related toxicity. Unfortunately, the roles of other polymorphisms in the DPYD gene in the severe 5-FU-related toxicity are not clarified. [Pg.66]

See other pages where Clinical utility, genetic testing is mentioned: [Pg.8]    [Pg.596]    [Pg.228]    [Pg.112]    [Pg.159]    [Pg.183]    [Pg.276]    [Pg.320]    [Pg.69]    [Pg.215]    [Pg.176]    [Pg.31]    [Pg.42]    [Pg.252]    [Pg.183]    [Pg.679]    [Pg.126]    [Pg.70]    [Pg.217]    [Pg.12]    [Pg.228]    [Pg.166]    [Pg.288]    [Pg.379]    [Pg.381]    [Pg.194]    [Pg.348]    [Pg.252]    [Pg.266]    [Pg.54]    [Pg.30]    [Pg.106]    [Pg.205]    [Pg.185]    [Pg.451]    [Pg.13]    [Pg.203]    [Pg.1324]    [Pg.69]    [Pg.79]    [Pg.480]    [Pg.13]    [Pg.576]    [Pg.286]    [Pg.263]    [Pg.56]    [Pg.105]    [Pg.1796]   
See also in sourсe #XX -- [ Pg.175 , Pg.176 ]



SEARCH



Clinical genetics

Clinical testing

Clinical tests

Tests genetic

© 2024 chempedia.info